Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 21 | 2016 | 916 | 2.750 |
Why?
|
| Mitral Valve Insufficiency | 7 | 2020 | 85 | 2.740 |
Why?
|
| Stroke Volume | 13 | 2020 | 332 | 1.550 |
Why?
|
| Mitral Valve | 5 | 2020 | 118 | 1.350 |
Why?
|
| Ventricular Function, Left | 9 | 2016 | 270 | 1.330 |
Why?
|
| Hypertrophy, Left Ventricular | 11 | 2012 | 124 | 1.330 |
Why?
|
| Heart Ventricles | 12 | 2009 | 264 | 0.870 |
Why?
|
| Echocardiography, Doppler | 9 | 2020 | 134 | 0.750 |
Why?
|
| Adrenergic beta-Antagonists | 5 | 2007 | 150 | 0.700 |
Why?
|
| Adenosine | 4 | 2004 | 78 | 0.680 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2017 | 165 | 0.620 |
Why?
|
| Hemodynamics | 4 | 2016 | 248 | 0.620 |
Why?
|
| Myocardial Contraction | 10 | 2012 | 88 | 0.610 |
Why?
|
| Norepinephrine | 3 | 2004 | 102 | 0.580 |
Why?
|
| Blood Pressure | 8 | 2014 | 509 | 0.580 |
Why?
|
| Ventricular Remodeling | 5 | 2018 | 83 | 0.530 |
Why?
|
| Double Outlet Right Ventricle | 1 | 2016 | 4 | 0.520 |
Why?
|
| Hypertension | 4 | 2012 | 584 | 0.520 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2016 | 13 | 0.500 |
Why?
|
| Models, Cardiovascular | 1 | 2016 | 79 | 0.490 |
Why?
|
| Hemofiltration | 1 | 2014 | 18 | 0.450 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 66 | 0.440 |
Why?
|
| Echocardiography | 11 | 2017 | 501 | 0.430 |
Why?
|
| Renal Dialysis | 1 | 2014 | 198 | 0.410 |
Why?
|
| Myocardium | 7 | 2004 | 274 | 0.400 |
Why?
|
| Lectins, C-Type | 1 | 2013 | 89 | 0.400 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 136 | 0.400 |
Why?
|
| Diastole | 7 | 2017 | 91 | 0.390 |
Why?
|
| Outpatients | 1 | 2013 | 142 | 0.390 |
Why?
|
| Male | 38 | 2016 | 29821 | 0.380 |
Why?
|
| Systole | 9 | 2012 | 109 | 0.380 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2007 | 143 | 0.350 |
Why?
|
| Aged | 25 | 2016 | 14394 | 0.350 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 1543 | 0.340 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2012 | 619 | 0.340 |
Why?
|
| Heart | 4 | 2000 | 282 | 0.340 |
Why?
|
| Decision Making | 1 | 2014 | 407 | 0.340 |
Why?
|
| Humans | 43 | 2020 | 63297 | 0.330 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 506 | 0.330 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2004 | 57 | 0.310 |
Why?
|
| Mitral Valve Annuloplasty | 2 | 2020 | 19 | 0.310 |
Why?
|
| Female | 31 | 2016 | 32791 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 695 | 0.300 |
Why?
|
| Rats | 9 | 2012 | 1977 | 0.300 |
Why?
|
| Massachusetts | 11 | 2016 | 2077 | 0.290 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2018 | 185 | 0.290 |
Why?
|
| Coronary Disease | 2 | 2003 | 246 | 0.280 |
Why?
|
| Chronic Disease | 3 | 2017 | 753 | 0.270 |
Why?
|
| Prognosis | 6 | 2014 | 1749 | 0.270 |
Why?
|
| Receptors, Purinergic P1 | 2 | 2004 | 12 | 0.270 |
Why?
|
| Survival Analysis | 2 | 2020 | 581 | 0.260 |
Why?
|
| Pacemaker, Artificial | 2 | 2013 | 49 | 0.250 |
Why?
|
| Ventricular Pressure | 4 | 2007 | 30 | 0.240 |
Why?
|
| Middle Aged | 21 | 2016 | 17553 | 0.240 |
Why?
|
| Angina, Unstable | 1 | 2005 | 58 | 0.230 |
Why?
|
| Cardiomyopathies | 2 | 2009 | 123 | 0.230 |
Why?
|
| Aortic Valve | 3 | 2002 | 190 | 0.230 |
Why?
|
| Presynaptic Terminals | 1 | 2004 | 37 | 0.220 |
Why?
|
| Propanolamines | 1 | 2004 | 10 | 0.220 |
Why?
|
| Carbazoles | 1 | 2004 | 13 | 0.220 |
Why?
|
| Metoprolol | 1 | 2004 | 15 | 0.220 |
Why?
|
| Tetrazoles | 1 | 2004 | 22 | 0.220 |
Why?
|
| Shock, Cardiogenic | 1 | 2005 | 102 | 0.220 |
Why?
|
| Cardiomegaly | 2 | 2001 | 34 | 0.220 |
Why?
|
| Life Style | 1 | 2006 | 311 | 0.220 |
Why?
|
| Benzimidazoles | 1 | 2004 | 54 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 738 | 0.200 |
Why?
|
| Antihypertensive Agents | 1 | 2004 | 166 | 0.200 |
Why?
|
| Myocardial Infarction | 3 | 2005 | 914 | 0.200 |
Why?
|
| Dexfenfluramine | 1 | 2002 | 5 | 0.190 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2002 | 13 | 0.190 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 2 | 0.190 |
Why?
|
| Adrenergic Antagonists | 1 | 2001 | 3 | 0.180 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2018 | 36 | 0.180 |
Why?
|
| Hodgkin Disease | 1 | 2001 | 55 | 0.180 |
Why?
|
| Receptors, Adrenergic | 1 | 2000 | 8 | 0.170 |
Why?
|
| Heart Valve Diseases | 1 | 2001 | 95 | 0.170 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2000 | 26 | 0.160 |
Why?
|
| Heart Failure, Diastolic | 2 | 2010 | 9 | 0.160 |
Why?
|
| Disease Progression | 4 | 2012 | 1168 | 0.160 |
Why?
|
| Treatment Outcome | 4 | 2020 | 5656 | 0.150 |
Why?
|
| Dipyridamole | 1 | 1998 | 17 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1998 | 20 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2013 | 2458 | 0.150 |
Why?
|
| Protein Kinase C | 1 | 1998 | 102 | 0.140 |
Why?
|
| Comorbidity | 5 | 2016 | 1121 | 0.140 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 59 | 0.140 |
Why?
|
| Coronary Vessels | 2 | 1999 | 118 | 0.140 |
Why?
|
| Coronary Artery Bypass | 2 | 2018 | 297 | 0.130 |
Why?
|
| Aged, 80 and over | 9 | 2007 | 5446 | 0.130 |
Why?
|
| Recurrence | 2 | 2018 | 642 | 0.130 |
Why?
|
| In Vitro Techniques | 3 | 2004 | 488 | 0.130 |
Why?
|
| Survival Rate | 3 | 2016 | 849 | 0.130 |
Why?
|
| Cardiac Catheterization | 2 | 2018 | 281 | 0.130 |
Why?
|
| Atrial Function, Left | 1 | 2016 | 33 | 0.130 |
Why?
|
| Mitoxantrone | 1 | 2016 | 16 | 0.130 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2016 | 26 | 0.120 |
Why?
|
| Diuretics | 2 | 2007 | 62 | 0.120 |
Why?
|
| Health Services Administration | 1 | 2015 | 4 | 0.120 |
Why?
|
| Heart Function Tests | 1 | 1995 | 15 | 0.120 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2018 | 172 | 0.120 |
Why?
|
| Animals | 10 | 2012 | 20631 | 0.120 |
Why?
|
| Health Services | 1 | 2015 | 82 | 0.120 |
Why?
|
| Cause of Death | 2 | 2013 | 221 | 0.110 |
Why?
|
| Thoracic Surgery | 1 | 2015 | 71 | 0.110 |
Why?
|
| Uncertainty | 1 | 2014 | 37 | 0.110 |
Why?
|
| Chi-Square Distribution | 3 | 2010 | 417 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2016 | 477 | 0.110 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2013 | 4 | 0.110 |
Why?
|
| Obesity | 1 | 2002 | 1230 | 0.110 |
Why?
|
| Biomarkers | 2 | 2013 | 1397 | 0.100 |
Why?
|
| Cardiology | 1 | 2015 | 167 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 317 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 192 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 1994 | 118 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 735 | 0.100 |
Why?
|
| Heart Failure, Systolic | 2 | 2010 | 16 | 0.100 |
Why?
|
| Purinergic P1 Receptor Agonists | 2 | 2004 | 6 | 0.100 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2013 | 5 | 0.100 |
Why?
|
| Hepatic Veins | 1 | 2013 | 13 | 0.100 |
Why?
|
| ROC Curve | 1 | 2013 | 281 | 0.100 |
Why?
|
| Ventricular Function | 2 | 2007 | 22 | 0.100 |
Why?
|
| Hospitalization | 3 | 2010 | 1359 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 1995 | 264 | 0.100 |
Why?
|
| Prevalence | 4 | 2010 | 1377 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2013 | 95 | 0.090 |
Why?
|
| Patient Participation | 1 | 2014 | 230 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 1146 | 0.090 |
Why?
|
| Stress, Mechanical | 2 | 2009 | 112 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2009 | 6630 | 0.090 |
Why?
|
| Perfusion | 3 | 2001 | 72 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2015 | 519 | 0.090 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 265 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1083 | 0.080 |
Why?
|
| Peripheral Arterial Disease | 1 | 2013 | 172 | 0.080 |
Why?
|
| Ultrasonography | 3 | 2009 | 483 | 0.080 |
Why?
|
| Acute Disease | 2 | 2010 | 672 | 0.080 |
Why?
|
| Hospital Mortality | 3 | 2005 | 874 | 0.080 |
Why?
|
| Organ Size | 2 | 2001 | 172 | 0.080 |
Why?
|
| Pericardium | 2 | 2000 | 35 | 0.080 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2009 | 49 | 0.070 |
Why?
|
| Age Factors | 2 | 2007 | 1559 | 0.070 |
Why?
|
| Heart Valve Prosthesis | 2 | 2002 | 112 | 0.070 |
Why?
|
| Body Weight | 2 | 2001 | 377 | 0.070 |
Why?
|
| Coronary Circulation | 2 | 2001 | 52 | 0.070 |
Why?
|
| Conscious Sedation | 2 | 2004 | 39 | 0.070 |
Why?
|
| Inpatients | 1 | 2010 | 303 | 0.070 |
Why?
|
| Logistic Models | 2 | 2010 | 1275 | 0.070 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2007 | 10 | 0.070 |
Why?
|
| Risk Factors | 4 | 2016 | 5343 | 0.070 |
Why?
|
| Reference Values | 2 | 2007 | 335 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2007 | 2180 | 0.060 |
Why?
|
| Heart Rate | 3 | 2007 | 321 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2013 | 3285 | 0.060 |
Why?
|
| Electrocardiography | 2 | 2003 | 554 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 178 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2007 | 206 | 0.060 |
Why?
|
| Aging | 2 | 2003 | 746 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 608 | 0.060 |
Why?
|
| Age Distribution | 1 | 2006 | 259 | 0.060 |
Why?
|
| Necrosis | 2 | 2003 | 143 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 972 | 0.060 |
Why?
|
| Urban Population | 1 | 2005 | 193 | 0.060 |
Why?
|
| Coronary Angiography | 3 | 2009 | 201 | 0.050 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2004 | 110 | 0.050 |
Why?
|
| Electric Countershock | 1 | 2004 | 101 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2007 | 1006 | 0.050 |
Why?
|
| Incidence | 4 | 2016 | 1375 | 0.050 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2003 | 9 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 2003 | 42 | 0.050 |
Why?
|
| Rhabdomyolysis | 1 | 2003 | 23 | 0.050 |
Why?
|
| Viridans Streptococci | 1 | 2002 | 5 | 0.050 |
Why?
|
| Troponin I | 1 | 2003 | 36 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 860 | 0.050 |
Why?
|
| Syndrome | 1 | 2003 | 180 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 139 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 474 | 0.050 |
Why?
|
| Streptococcal Infections | 1 | 2002 | 80 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 453 | 0.050 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2002 | 43 | 0.050 |
Why?
|
| Abscess | 1 | 2002 | 79 | 0.050 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2001 | 4 | 0.040 |
Why?
|
| Inosine | 1 | 2001 | 4 | 0.040 |
Why?
|
| Isoproterenol | 1 | 2001 | 36 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2001 | 33 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2001 | 200 | 0.040 |
Why?
|
| Caffeine | 1 | 2001 | 49 | 0.040 |
Why?
|
| Myocardial Reperfusion | 1 | 2000 | 24 | 0.040 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2000 | 23 | 0.040 |
Why?
|
| Endocardium | 1 | 1999 | 13 | 0.040 |
Why?
|
| Survival | 1 | 1998 | 11 | 0.040 |
Why?
|
| Registries | 1 | 2002 | 888 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 1998 | 380 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 1649 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2009 | 1121 | 0.030 |
Why?
|
| Calcium | 1 | 2001 | 573 | 0.030 |
Why?
|
| Heart Diseases | 1 | 1999 | 217 | 0.030 |
Why?
|
| United States | 3 | 2009 | 7828 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2001 | 2152 | 0.030 |
Why?
|
| Syncope | 1 | 1996 | 42 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 58 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2004 | 837 | 0.030 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2015 | 8 | 0.030 |
Why?
|
| Bioprosthesis | 1 | 1996 | 42 | 0.030 |
Why?
|
| Time Factors | 3 | 2009 | 3761 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1994 | 28 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 311 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1994 | 112 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2010 | 768 | 0.030 |
Why?
|
| Aorta | 1 | 1994 | 113 | 0.030 |
Why?
|
| Lung | 1 | 1998 | 953 | 0.030 |
Why?
|
| Dogs | 1 | 1994 | 325 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 75 | 0.020 |
Why?
|
| Device Removal | 1 | 2013 | 67 | 0.020 |
Why?
|
| Adult | 5 | 2009 | 16781 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 663 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 2009 | 53 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2009 | 270 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 1618 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2009 | 193 | 0.020 |
Why?
|
| Midazolam | 1 | 2004 | 12 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2004 | 37 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2009 | 469 | 0.010 |
Why?
|
| Anesthetics, Intravenous | 1 | 2004 | 26 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 156 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 214 | 0.010 |
Why?
|
| Fentanyl | 1 | 2004 | 76 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 2077 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 2570 | 0.010 |
Why?
|
| Demography | 1 | 2002 | 173 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2002 | 168 | 0.010 |
Why?
|
| Survivors | 1 | 2002 | 170 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2002 | 209 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 1539 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2000 | 53 | 0.010 |
Why?
|
| Disease Management | 1 | 2002 | 232 | 0.010 |
Why?
|
| Myocardial Revascularization | 1 | 1999 | 76 | 0.010 |
Why?
|
| Hospitals | 1 | 2002 | 392 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 104 | 0.010 |
Why?
|
| Observer Variation | 1 | 1999 | 213 | 0.010 |
Why?
|
| Tilt-Table Test | 1 | 1996 | 11 | 0.010 |
Why?
|
| Mechanoreceptors | 1 | 1996 | 13 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2003 | 2571 | 0.010 |
Why?
|
| Aortic Valve Stenosis | 1 | 1996 | 188 | 0.010 |
Why?
|